Direct Hugel Supply Chain
Botulax sourced from Korean supply channels; factory-sealed vials with original Hugel packaging and labeling.
Botulax Wholesale: Hugel Korean Botox for B2B Clinic Supply
Botulax (internationally registered as Letybo in the US and Europe) is a Korean botulinum toxin type A from Hugel Inc., the market leader in South Korea for 9 consecutive years. Clinics ordering Botulax wholesale access a 900 kDa CBFC26-strain toxin available in 100U, 200U, and 300U formats to match a full range of aesthetic and therapeutic protocols.
Table of Contents
- Botulax Wholesale Supply for Clinics and Distributors
- Botulax Export Timeline
- Botulax Quick Product Specs
- Botulax Variants & Comparison Matrix
- Botulax Evidence & Documentation
- Botulax Authenticity Checklist
- What is Botulax? Corporate Profile
- Botulax Mechanism of Action
- Botulax Target Areas & Indications
- Preparation & Reconstitution
- Botulax Clinical Advantages
- Botulax Visible Improvements
- Storage & Safety
- Hugel R&D Pipeline
- Wholesale Botox
- Frequently Asked Questions (FAQ)
Botulax Wholesale: Hugel's Korean Botox for Clinical Supply
Hugel Inc. holds the number one market share in South Korea for 9 consecutive years since 2016 — a position built on consistent manufacturing quality and global regulatory investment. Botulax is the only Korean botulinum toxin simultaneously approved in the US, China, and Europe, with an export footprint spanning 70+ countries. Clinics buying Botulax wholesale access this pedigree directly through Korean B2B sourcing, without secondary reseller markup.
The three-vial portfolio (100U, 200U, 300U) gives clinics portfolio flexibility — matching session types rather than forcing fixed unit sizes. For buyers comparing Botox wholesale options, Botulax offers a clinically validated, cost-competitive alternative from the world's leading Korean toxin manufacturer.
Three-Size Vial Portfolio
100U for standard aesthetic sessions, 200U for high-volume or multi-area work, 300U for therapeutic protocols — all procurable in one bulk order.
Cold-Chain Commitment
2-8°C maintained throughout dispatch with temperature-controlled insulation for all air freight and express shipments.
Key Export Destinations
United States, Canada, United Kingdom, Germany, Poland, France, Italy, Spain, Albania, UAE (Dubai), Saudi Arabia, Qatar, Kuwait, Turkey, Brazil, Colombia, Argentina, Mexico, Thailand, Japan, Australia.
For clinics planning a first-time Botulax bulk order or restocking an existing account, we help match unit sizes, quantity, and export route before quoting. See the full Botox wholesale category for related toxin options.
Botulax Export Timeline for B2B Buyers
Botulax procurement follows a quote-led B2B export workflow rather than a public cart checkout — ensuring cold-chain compliance and destination-specific handling at every step.
-
Product & Unit Inquiry
The clinic or distributor specifies the required 100U/200U/300U mix, destination country, and estimated monthly volume.
-
Supply Status Check
We confirm cold-chain stock availability, export window, and variant availability before the buyer finalizes the order.
-
Order Creation
Proforma invoice is issued with unit sizes, quantity, pricing, and destination details.
-
Payment Confirmation
After payment confirmation, the order moves to cold-chain packing and dispatch preparation.
-
Cold-Chain Dispatch
Shipped via FedEx International Priority, EMS, air freight, or container with temperature-controlled insulation maintaining 2-8°C throughout transit.
-
Delivery & Reorder Planning
Tracking information is shared after handoff. We support next Botulax bulk order planning based on usage rate and remaining inventory.
Botulax Quick Product Specs
Manufacturer Hugel Inc., South Korea
Product Type Botulinum toxin type A (CBFC26 strain), 900 kDa complex
Variants 100 Units, 200 Units, 300 Units
International Name Letybo (United States and Europe)
Regulatory Status KFDA, US FDA (2024 cGMP approval), EU EMA GMP (2021)
Export Footprint 70+ countries; only Korean toxin in US, China, and Europe simultaneously
Storage Range 2-8°C; once reconstituted, use within 24 hours at 2-8°C
Shelf Life 36 months from manufacture (certain therapeutic presentations: 24 months)
Best-Fit Buyer Clinics and distributors planning aesthetic and therapeutic toxin inventory
Botulax Variants & Comparison Matrix
The Botulax portfolio covers three vial sizes differentiated by dose capacity and clinical application. This comparison helps clinics select the right mix before placing a Botulax wholesale order.
| Variant | Best for | Depth / Area | Needle | Lidocaine | Procurement note |
|---|---|---|---|---|---|
| Botulax 100 Units | Standard facial aesthetics, single-patient sessions | Facial planes (glabella, crow's feet, forehead) | 30G | N/A | Best for routine clinic scheduling, low per-session wastage |
| Botulax 200 Units | High-volume clinics, masseter / hyperhidrosis | Larger muscle groups, multi-area | 30G | N/A | Economical per-unit for busy schedules; fewer vials per session |
| Botulax 300 Units | Therapeutic protocols, heavy indications | Spasticity, pediatric cerebral palsy | 27G | N/A | Reduces vial count for high-dose therapeutic sessions |
Botulax 100 Units
Specs: CBFC26 strain, 900 kDa, 30G needle
Botulax 100 Units is the standard choice for aesthetic facial protocols — glabellar lines, crow's feet, and forehead — where precise low-dose delivery matters. Ideal for clinics with consistent single-patient session volume.
Most Ordered 
Botulax 200 Units
Specs: CBFC26 strain, 900 kDa, 30G needle
Botulax 200 Units suits high-volume aesthetic clinics scheduling multiple back-to-back patients or treating larger muscle groups such as masseter reduction and hyperhidrosis. Reduces vial count per session.
Botulax 300 Units
Specs: CBFC26 strain, 900 kDa, 27G needle
Botulax 300 Units is primarily used for high-dose therapeutic indications: post-stroke upper limb spasticity (max 360U per session), pediatric cerebral palsy equinus foot deformity (4-6 U/kg), and blepharospasm protocols. Reduces overall vial count when high total doses are required.
Botulax Evidence & Documentation
Official Hugel documents support clinical positioning and product verification for Botulax wholesale buyers.
Botulax Global Standard Brochure
Hugel corporate and regulatory positioning document covering Botulax global market approvals and clinical positioning.
View Global Standard PDFOfficial Botulax / Letybo Brochure
Product brochure covering formulation details, clinical indications, dilution protocols, and safety profile for Botulax and Letybo.
View Official BrochureBotulax Authenticity Checklist
Before using received Botulax stock, wholesale buyers should verify the following packaging and labeling points.
Factory-Sealed Vial Packaging
Check the holographic foil seal on the outer carton, verify vial cap integrity, and confirm the product name on the outer carton matches Botulax or Letybo as expected for your market.
Lot Number & Expiry Verification
Verify lot number consistency between the outer carton and the vial label. Expiry must align with expected export shelf life — any discrepancy warrants rejection before use.
Product Image Confirmation
Confirm vial appearance, label print quality, and packaging format match official Hugel product imagery before use. Any packaging damage or print irregularities are grounds for rejecting the shipment.
What is Botulax? Corporate Profile
Botulax is a botulinum toxin type A injectable produced by Hugel Inc., a South Korean biopharmaceutical company headquartered in Seoul. Hugel has held the number one market share in the Korean botulinum toxin market for 9 consecutive years since 2016 — a position underpinned by consistent manufacturing quality, enzyme-free purification, and sustained global regulatory investment.
The active strain used in Botulax is CBFC26, delivered in a 900 kDa protein complex. The formulation is registered under the brand name Letybo in the United States and Europe, making it identical in formulation to Botulax but distinguished by market-specific regulatory submissions. Hugel received US FDA cGMP approval in 2024 and EU EMA GMP certification in 2021, completing a three-market approval footprint unique among Korean toxin manufacturers.
Botulax is now exported to 70+ countries. In 2025, Hugel reported total net sales of 425.1 billion KRW — up 14% year-over-year — with Americas sales growing 105%, driven by Letybo uptake in the US market. This financial trajectory reflects the growing international adoption of Hugel's Korean Botox products across both aesthetic and therapeutic categories.
Botulax Mechanism of Action
Synaptic Blockade at the Neuromuscular Junction
Botulax works by blocking acetylcholine release at the neuromuscular junction. After injection, the toxin binds to presynaptic nerve terminals, undergoes endocytosis, and cleaves SNAP-25 — a SNARE protein required for vesicle fusion and neurotransmitter release. This prevents muscle contraction at the injection site.
The CBFC26 strain used in Botulax has been selected for consistency of binding and predictable diffusion behavior. Muscle activity typically begins to return as nerve sprouting and new receptor formation reestablish normal synaptic function over 3-6 months.
Enzyme-Free Purification Process
Botulax uses an enzyme-free purification process that removes animal-derived proteins and nucleic acids without using additional enzymatic steps. This minimizes immunogenic residues that could otherwise trigger neutralizing antibody formation in patients on long-term treatment protocols.
- Strain: CBFC26, proprietary to Hugel Inc.
- Complex weight: 900 kDa (full protein complex)
- Excipients: Human serum albumin and sodium chloride
- Neutralizing antibodies: Zero detected in clinical safety studies
Botulax Target Areas & Indications
Botulax covers both aesthetic and therapeutic indications. The 100U and 200U vials are primarily used in aesthetic facial work; the 300U vial is the standard choice for high-dose therapeutic protocols.
Aesthetic Indications
- Glabellar frown lines (primary indication)
- Lateral canthal lines (crow's feet)
- Forehead horizontal lines
- Masseter reduction (facial slimming)
- Hyperhidrosis (axillary, palmar)
- Brow lift and perioral lines
Therapeutic Indications
- Post-stroke upper limb spasticity (max 360U/session)
- Pediatric cerebral palsy — equinus foot deformity (4-6 U/kg)
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
Preparation & Reconstitution
Botulax is supplied as a lyophilized powder requiring reconstitution with sterile 0.9% sodium chloride (saline) immediately before use. The reconstitution volume determines the final concentration per injection.
| Saline Added (mL) | Resulting Concentration | Typical Use |
|---|---|---|
| 1.0 mL | 10 U per 0.1 mL | High-concentration therapeutic use |
| 2.0 mL | 5 U per 0.1 mL | Standard aesthetic dosing |
| 2.5 mL | 4 U per 0.1 mL | Standard glabellar protocol (20U across 5 sites) |
| 4.0 mL | 2.5 U per 0.1 mL | Dilute dosing for fine areas |
| 8.0 mL | 1.25 U per 0.1 mL | Ultra-dilute superficial applications |
Glabellar Protocol
- 5 injection sites across the glabellar complex
- 4 U per site = 20U total (standard adult dose)
- 1 cm safety margin from the superior orbital rim
- 30-gauge needle, intramuscular injection
- Post-injection: 30-minute clinical observation for immediate hypersensitivity
Reconstitution Guidelines
- Use only preservative-free 0.9% NaCl for reconstitution
- Do not shake — gently swirl to dissolve
- Reconstituted solution must be clear and colorless
- Use within 24 hours; store at 2-8°C if not used immediately
- Drug interactions: Aminoglycosides and Spectinomycin are contraindicated as they potentiate neuromuscular blockade
Botulax Clinical Advantages & Non-Inferiority Data
The decision to use Botulax wholesale stock over other toxin lines is supported by Phase III randomized clinical trial data and direct comparisons against onabotulinumtoxinA (Botox).
Chinese Phase III non-inferiority trial: In a double-blind Phase III study conducted in China, Botulax achieved an 88.49% success rate versus 87.39% for Botox at a stringent 10% noninferiority margin — confirming clinical equivalence under rigorous controlled conditions.
Patient satisfaction at Week 4: Patient self-reported satisfaction reached 92.88% for Botulax at Week 4 — trending above the Botox group in the same trial.
Lower adverse event rate: Total adverse events in the Botulax group were 37.8% versus 43.4% in the Botox group, supporting a favorable safety profile across the trial population.
Zero neutralizing antibodies: In Hugel's clinical safety studies, no patients developed neutralizing antibodies against Botulax — a significant long-term safety finding for patients on repeat treatment schedules.
Botulax Visible Improvements (Before & After)
Consistent Botulax wholesale inventory supports predictable treatment planning for aesthetic clinics. The following visual examples show glabellar and crow's feet improvement outcomes for reference when planning Botulax stock levels.
Storage & Safety
Storage Requirements
- Unopened vials: 2-8°C; do not freeze
- Reconstituted solution: Use within 24 hours at 2-8°C
- Shelf life: 36 months from manufacture (24 months for certain therapeutic presentations)
- Light protection: Store in original carton; protect from UV exposure
- Transport: Cold-chain insulated packaging required; do not allow vials to exceed 25°C during transit
Contraindications & Precautions
- Known hypersensitivity to botulinum toxin type A or any excipient
- Infection at the proposed injection site
- Neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton syndrome)
- Drug interactions: Aminoglycosides and Spectinomycin potentiate neuromuscular blockade — contraindicated
- Pregnancy and breastfeeding: use only if clearly necessary
- Post-injection observation: 30 minutes for immediate hypersensitivity
Hugel R&D Pipeline
Hugel's toxin pipeline extends beyond the current Botulax formulation, with three next-generation candidates in active development that address clinical limitations of the current standard.
HG102 — Liquid + Lidocaine (Phase 1 Complete)
A liquid-formulated botulinum toxin with integrated lidocaine that eliminates the reconstitution step required for lyophilized Botulax. Phase 1 clinical studies have been completed. Aimed at improving procedural efficiency and reducing preparation errors in high-volume clinical settings.
HG103 — Microneedle Patch (Preclinical)
A transdermal microneedle patch delivery system for botulinum toxin. Targets needle-averse patients and superficial skin texture applications where injection-based delivery is suboptimal. Preclinical development ongoing.
HG105 — Pure 150 kDa (Preclinical)
A purified 150 kDa botulinum toxin free of the accessory proteins that make up the 900 kDa complex. By eliminating the accessory protein scaffold, HG105 targets neutralizing antibody risk at its source — relevant for patients on long-term high-dose therapeutic regimens who may develop immunological resistance over time.
Botulax Wholesale FAQ
Wholesale & MOQ
How can clinics request Botulax wholesale pricing and MOQ details?
Contact via WhatsApp with your required unit sizes (100U/200U/300U or mixed), destination country, and estimated monthly volume. Pricing is structured around order volume and export route.
Can we order Botulax 100U, 200U, and 300U together in one bulk shipment?
Yes. Mixed unit orders are standard. All three sizes can be combined in a single Botulax bulk order, priced by total vial count and destination.
Shipping & Storage
What cold-chain conditions are required for Botulax export?
Botulax must be maintained at 2-8°C from dispatch to clinic delivery. We use temperature-controlled insulated packaging for all air freight shipments. FedEx International Priority and EMS are primary carriers; sea container routing is available for large distributor volumes.
What is the shelf life of Botulax?
36 months from manufacture for most formats. Certain therapeutic presentations are marked at 24 months. Once reconstituted, use within 24 hours and store at 2-8°C.
Authenticity
Is Botulax the same product as Letybo?
Yes. Botulax and Letybo are identical formulations manufactured by Hugel Inc. The brand name differs by market — Botulax is used in Korea and international markets; Letybo is the registered name in the United States and Europe.
How do I verify that received Botulax stock is authentic?
Check the holographic foil seal on the carton, verify lot number consistency between the outer box and vial label, and confirm product appearance matches official Hugel product imagery. Any packaging damage or print irregularities warrant rejection.
Variants
Which Botulax unit size is most suitable for aesthetic facial work?
Botulax 100 Units is the standard choice for aesthetic facial protocols — glabellar lines, crow's feet, forehead — where precise low-dose delivery matters. Botulax 200 Units suits clinics scheduling multiple back-to-back patients or treating larger muscle groups.
What is Botulax 300 Units used for?
Botulax 300 Units is primarily used for high-dose therapeutic indications: post-stroke upper limb spasticity (max 360U per session), pediatric cerebral palsy equinus foot deformity (4-6 U/kg), and blepharospasm protocols. It reduces vial count when high total doses are required.
Clinical Overview
How does Botulax compare to Botox (OnabotulinumtoxinA) clinically?
Phase III trials confirm Botulax is non-inferior to Botox in both efficacy and safety. In the Chinese double-blind Phase III study, Botulax achieved an 88.49% success rate vs 87.39% for Botox at a stringent 10% noninferiority margin. Patient self-reported satisfaction trended higher for Botulax at 92.88% at Week 4.
Are neutralizing antibodies a concern with repeated Botulax use?
Clinical safety data for Botulax reports zero development of neutralizing antibodies in observed patients. The enzyme-free purification process removes animal-derived proteins and nucleic acids, minimizing immunogenic risk for patients on long-term treatment protocols.
What is the onset and duration of Botulax?
Aesthetic results typically appear within 3 days, reaching peak efficacy at 1-4 weeks. Duration ranges from 3-6 months depending on injection site, patient metabolism, and dosage.